Abdoulaye Karaboué - Concepedia

Author

Abdoulaye Karaboué

Also Known As

A. Karaboue, A. Karaboué, Abdoulaye Karaboue, Abdoulaye Karaboué, Francis Lévi, Karaboue Abdoulaye, Karaboué Abdoulaye, Karaboué, Abdoulaye

Publications

1.5K

Citations

H-Index

Concepts

All Affiliations

Hôpital Paul-Brousse Assistance Publique – Hôpitaux de Paris Inserm Groupe Hospitalier Intercommunal Le Raincy Montfermeil Université Paris-Sud

About

Abdoulaye Karaboué is an author at Hôpital Paul-Brousse specializing in medicine, oncology, and colorectal cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	447
2	Nursing	1	1	17
3	Public Health	1	1	17
4	Health Informatics	1	1	17
5	Health Information Technology	1	1	17

Abdoulaye Karaboué

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV Françis Lévi, Valérie Boige, Mohamed Hebbar, Annals of Oncology Surgical OncologyHepatologyGastrointestinal OncologyMedicineHepatic Artery Infusion	2015	140
Wrist actimetry circadian rhythm as a robust predictor of colorectal cancer patients survival Françis Lévi, Pierre‐Antoine Dugué, Pasquale F. Innominato, Chronobiology International	2014	109
Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer Abdoulaye Karaboué, T. Collon, Ida Pavese, Cancers	2022	82
Circadian rest‐activity rhythm as an objective biomarker of patient‐reported outcomes in patients with advanced cancer Pasquale F. Innominato, Sandra Komarzynski, Oxana Palesh, Cancer Medicine	2018	74
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer Mohamed Bouchahda, Teresa Macarulla, J.P. Spano, Critical Reviews in Oncology/Hematology Cetuximab EfficacyElderly PatientsGastrointestinal OncologyMedicineCancer Management	2008	69
Acquired KRAS mutations during progression of colorectal cancer metastases: possible implications for therapy and prognosis Mohamed Bouchahda, Abdoulaye Karaboué, Raphaël Saffroy, Cancer Chemotherapy and Pharmacology Kras MutationsMedicinePossible ImplicationsColorectal CancerPathology	2010	64
Sex‐dependent least toxic timing of irinotecan combined with chronomodulated chemotherapy for metastatic colorectal cancer: Randomized multicenter EORTC 05011 trial Pasquale F. Innominato, Annabelle Ballesta, Qi Huang, Cancer Medicine	2020	63
The circadian rest‐activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy Elisabet Ortiz‐Tudela, Ida Iurisci, J Le Beau, International Journal of Cancer	2013	59
Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability Françis Lévi, Abdoulaye Karaboué, Lee Gorden, Cancer Chemotherapy and Pharmacology Surgical OncologyGastrointestinal OncologyMedicineSalvage TreatmentColorectal Cancer	2010	46
Skin surface temperature rhythms as potential circadian biomarkers for personalized chronotherapeutics in cancer patients Christopher G. Scully, Abdoulaye Karaboué, Wei‐Min Liu, Interface Focus	2010	46

Page 1